Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy

Detalles Bibliográficos
Autores principales: Azim, Adnan, Pini, Laura, Khakwani, Zeeshan, Kumar, Santosh, Howarth, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804376/
https://www.ncbi.nlm.nih.gov/pubmed/33453381
http://dx.doi.org/10.1016/j.anai.2021.01.006
_version_ 1783636150197420032
author Azim, Adnan
Pini, Laura
Khakwani, Zeeshan
Kumar, Santosh
Howarth, Peter
author_facet Azim, Adnan
Pini, Laura
Khakwani, Zeeshan
Kumar, Santosh
Howarth, Peter
author_sort Azim, Adnan
collection PubMed
description
format Online
Article
Text
id pubmed-7804376
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-78043762021-01-13 Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy Azim, Adnan Pini, Laura Khakwani, Zeeshan Kumar, Santosh Howarth, Peter Ann Allergy Asthma Immunol Letter American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. 2021-04 2021-01-13 /pmc/articles/PMC7804376/ /pubmed/33453381 http://dx.doi.org/10.1016/j.anai.2021.01.006 Text en © 2021 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter
Azim, Adnan
Pini, Laura
Khakwani, Zeeshan
Kumar, Santosh
Howarth, Peter
Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy
title Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy
title_full Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy
title_fullStr Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy
title_full_unstemmed Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy
title_short Severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy
title_sort severe acute respiratory syndrome coronavirus 2 infection in those on mepolizumab therapy
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804376/
https://www.ncbi.nlm.nih.gov/pubmed/33453381
http://dx.doi.org/10.1016/j.anai.2021.01.006
work_keys_str_mv AT azimadnan severeacuterespiratorysyndromecoronavirus2infectioninthoseonmepolizumabtherapy
AT pinilaura severeacuterespiratorysyndromecoronavirus2infectioninthoseonmepolizumabtherapy
AT khakwanizeeshan severeacuterespiratorysyndromecoronavirus2infectioninthoseonmepolizumabtherapy
AT kumarsantosh severeacuterespiratorysyndromecoronavirus2infectioninthoseonmepolizumabtherapy
AT howarthpeter severeacuterespiratorysyndromecoronavirus2infectioninthoseonmepolizumabtherapy

Ejemplares similares